Skip to main content
OpenTrials
Completed

NCT Number: NCT04151797

Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients

In patients aged 75 years and older, polypathology is frequent and often associated with polypharmacy. This polypharmacy coupled with a lack of proactive elderly care can sometimes lead to hospitalisation. Due to comorbidities and complex problems, management of geriatric patients usually requires a multidisciplinary approach. In Toulouse University Hospital, elderly inpatients can benefit from a geriatric assessment by a Geriatric Mobile Team. Whether this team improve the prescriptions through the advice of a clinical pharmacist has not been demonstrated yet.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Medication Therapy Management

Age range

75 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Toulouse University Hospital

Toulouse, Occitanie, 31059, France

About this study

All participants will be identified via the geriatrician of the mobile geriatric team with the following inclusion criteria: age ≥ 75 years, ≥ 5 medications per day and being hospitalised either in emergency room, short-stay medicine unit or in a surgery department. For each patient, the pharmacist will detect potentially inappropriate prescribing (based on explicit criteria and an implicit approach) and liaise with the geriatrician for drug optimisations. The pharmaceutical advice will be added to the geriatrician's written report, and then addressed to the relevant physician. The implementation of the proposals will be evaluated immediately at the end of hospitalisation, and then reassessed three months later by calling the patient and/or his community pharmacist. A total of 250 patients will be enrolled over a 12 month-period. The evolution of potentially inappropriate prescribing will be assessed and their cost evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 75 or older
  • Having 5 medications or more per day
  • Being hospitalised either in emergency room, short-stay medicine unit or surgery department

Exclusion criteria

  • Patient refuses to participate
  • Patient already included in another study

Treatment and study plan

Medication therapy management

Other

The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:

  • Data collection on comorbidities, medication and laboratory results.
  • A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.
  • A detailed feedback to the geriatrician.
  • A written report addressed to the attending physician

Primary outcomes

  1. Change from baseline patients' number of potentially inappropriate prescription at the patient discharge after optimization by a mobile geriatric team with pharmacist

    Time frame: Month 0 and max Month 2 (At the patient discharge)

    number of potentially inappropriate prescribing per patient before (month 0) and after the intervention of the mobile geriatric team (at the patient discharge)

Secondary outcomes

  1. Change from baseline patients' number of potentially inappropriate prescription at 3 months after optimization by a mobile geriatric team with pharmacist

    Time frame: Month 0, Month 3

    number of potentially inappropriate prescribing per patient before (month 0) and after the intervention of the mobile geriatric team (month 3)

  2. Change from baseline patients' number with at least one potentially inappropriate drug at 3 months after optimization by a mobile geriatric team with pharmacist

    Time frame: Month 0, Month 3

    number of patients with at least one potentially inappropriate drug before (month 0) and after the intervention of the mobile geriatric team (month 3)

  3. Change from baseline ratio of potentially inappropriate drug per patient at 3 months after optimization by a mobile geriatric team with pharmacist

    Time frame: Month 0, Month 3

    ratio of potentially inappropriate drug per patient before (month 0) and after (month 3) the intervention of the mobile geriatric team.

  4. Change from baseline mean number of medications per patient at 3 months

    Time frame: Month 0, Month 3

    Mean number of medications per patient

  5. realisation of a pharmacist-led medication review in primary care

    Time frame: Month 3

    Number of pharmacist-led medication review performed in primary care at 3 months

  6. number of falls 3 months after pharmacist-led medication review

    Time frame: Month 3

    Number of falls

  7. mortality 3 months after pharmacist-led medication review

    Time frame: Month 3

    Number of deaths

  8. re-hospitalisation, including emergency room transfers

    Time frame: Month 3

    Number of non-scheduled hospitalisations (including emergency department transfers)

  9. The nursing home transfers

    Time frame: Month 3

    Number of nursing home transfers

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: PHARMOG

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Nov 5, 2019
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.